Donepezil ( DrugBank: Donepezil )
9 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
5 | Progressive supranuclear palsy | 2 |
6 | Parkinson disease | 22 |
13 | Multiple sclerosis/Neuromyelitis optica | 4 |
46 | Malignant rheumatoid arthritis | 1 |
78 | Hypopituitarism | 1 |
124 | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy | 7 |
127 | Frontotemporal lobar degeneration | 1 |
156 | Rett syndrome | 2 |
206 | Fragile X syndrome | 2 |
5. Progressive supranuclear palsy
Clinical trials : 89 / Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2006-006166-42-DE (EUCTR) | 17/07/2007 | 02/01/2007 | Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie - | Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie - | Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and donepezil did not point out a definite benefit. In contrast, first clinical observations concerning an effect with rivastigmine in PSP with dementia were promising. This may be due to the fact, that rivastigmine excerts a double action inhibiting both the acetylcholin- and the buturylcholinesterase. | Trade Name: Exelon 1,5 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE Trade Name: Exelon 3,0 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE Trade Name: Exelon 6,0 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE | University of Tuebingen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Germany | |||
2 | NCT00139373 (ClinicalTrials.gov) | May 2005 | 30/8/2005 | Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy | Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy | Supranuclear Palsy, Progressive | Drug: donepezil | Groupe Hospitalier Pitie-Salpetriere | Institut National de la Santé Et de la Recherche Médicale, France | Recruiting | 30 Years | 80 Years | Both | 16 | Phase 2 | France |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05709301 (ClinicalTrials.gov) | April 1, 2023 | 11/1/2023 | Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease | Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease | Parkinson Disease;Mild Cognitive Impairment | Drug: Donepezil Hydrochloride;Drug: Placebo | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | NULL | Not yet recruiting | 50 Years | 80 Years | All | 120 | Phase 2 | NULL |
2 | NCT04117178 (ClinicalTrials.gov) | February 4, 2020 | 30/9/2019 | Monitoring Anti-Dementia Drugs by Serum Levels | Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title) | Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer Disease | Drug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drug | Zealand University Hospital | Epilepsihospitalet Filadelfia | Recruiting | 18 Years | N/A | All | 110 | Phase 4 | Denmark |
3 | NCT03599726 (ClinicalTrials.gov) | July 30, 2018 | 29/6/2018 | Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil | Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil | Parkinson Disease | Drug: Donepezil;Drug: Placebo | Oregon Health and Science University | Medical Research Foundation, Oregon | Completed | 50 Years | 90 Years | All | 20 | Early Phase 1 | United States |
4 | EUCTR2017-002707-10-DK (EUCTR) | 10/04/2018 | 03/11/2017 | Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effects | Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance | Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies MedDRA version: 20.0;Level: PT;Classification code 10012271;Term: Dementia Alzheimer's type;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10075174;Term: Mixed dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Memantin Orion INN or Proposed INN: MEMANTINE Product Name: Donepezil Sandoz Product Code: 25330 INN or Proposed INN: DONEPEZIL | Regional Dementia Research Centre, Dept of Neurology | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 110 | Phase 4 | Denmark | ||
5 | NCT03011476 (ClinicalTrials.gov) | April 11, 2017 | 27/12/2016 | Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease | Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance | Parkinson Disease | Drug: Donepezil;Drug: Placebos | Kyung Hee University Hospital | NULL | Unknown status | 40 Years | 75 Years | All | 20 | Phase 4 | Korea, Republic of |
6 | NCT02857244 (ClinicalTrials.gov) | November 2016 | 25/7/2016 | A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients | A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients | Parkinson's Disease | Drug: Duloxetine;Drug: Donepezil;Drug: Modafinil | University of Chicago | NULL | Withdrawn | 18 Years | 100 Years | All | 0 | Phase 2 | United States |
7 | NCT02415062 (ClinicalTrials.gov) | July 2015 | 14/3/2015 | The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia | The Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With Dementia | Parkinson's Disease | Drug: Donepezil | Inje University | NULL | Recruiting | 50 Years | 80 Years | Both | 150 | Phase 2 | Korea, Republic of |
8 | NCT02450786 (ClinicalTrials.gov) | June 2015 | 14/5/2015 | Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI) | Parkinson's Disease | Drug: Donepezil | Yonsei University | NULL | Active, not recruiting | 40 Years | N/A | All | 80 | Phase 2 | Korea, Republic of | |
9 | NCT02206620 (ClinicalTrials.gov) | July 2014 | 29/7/2014 | Effects of Cholinergic Augmentation on Measures of Balance and Gait | Effects of Cholinergic Augmentation on Measures of Balance and Gait | Parkinson's Disease | Drug: Donepezil | Oregon Health and Science University | Michael J. Fox Foundation for Parkinson's Research | Completed | 30 Years | N/A | All | 49 | Phase 2 | United States |
10 | JPRN-UMIN000010752 | 2013/05/17 | 17/05/2013 | A study on usefulness and safety of donepezil for cognitive function and phychological symptoms of patients with Parkinson's disease and Alzheimer type dementia. | A study on usefulness and safety of donepezil for cognitive function and phychological symptoms of patients with Parkinson's disease and Alzheimer type dementia. - Donepezil study on Parkinson\'s disease with dementia | Parkinson's disease | donepezil | Kansai Medical University | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 50 | Not selected | Japan |
11 | JPRN-UMIN000010778 | 2013/04/10 | 22/05/2013 | Delayed start study of donepezil hydrocloride for cognitive decline in Parkinson disease following EDAP-1 | Delayed start study of donepezil hydrocloride for cognitive decline in Parkinson disease following EDAP-1 - EDAP-2 | Parkinson disease | 5mg donepezil hydrocloride | National Hospital of Utano | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 50 | Not selected | Japan |
12 | JPRN-UMIN000009958 | 2013/03/08 | 01/03/2013 | Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction | Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction - Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction | Parkinson's disease | Donepezil hydrochloride added to standard therapy Placebo added to standard therapy | National Hospital Organization, Sendai-Nishitaga Hospital | NULL | Complete: follow-up complete | 55years-old | 75years-old | Male and Female | 200 | Not applicable | Japan |
13 | NCT01014858 (ClinicalTrials.gov) | January 2013 | 16/11/2009 | Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease | Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease | Parkinson's Disease | Drug: Donepezil | Newcastle-upon-Tyne Hospitals NHS Trust | University of Newcastle Upon-Tyne;University of Cambridge;University of Manchester;University of Birmingham;Bangor University;London School of Economics and Political Science;University College, London;Lancashire Care NHS Foundation Trust;Newcastle University;King's College London | Terminated | 18 Years | N/A | All | 64 | Phase 3 | United Kingdom |
14 | EUCTR2009-015170-35-GB (EUCTR) | 27/01/2012 | 21/12/2011 | Study across 22 UK hospitals investigating if a drug called Donepezil Hydrochloride can help people with an early form of Parkinson's Disease dementia. | Multicentre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated with Parkinson's Disease (MUSTARDD-PD) - Donepezil in Early Dementia Associated with Parkinson's Disease | Parkinson's disease with mild dementia (PDD);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Pridia (Donepezil Hydrochloride) 5mg Product Name: Pridia 5mg INN or Proposed INN: Donepezil hydrochloride Trade Name: Pridia 10mg Product Name: Pridia 10mg INN or Proposed INN: Donepezil hydrochloride | The Newcastle upon Tyne Hospitals NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 500 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United Kingdom | ||
15 | NCT01521117 (ClinicalTrials.gov) | December 2011 | 12/1/2012 | The Effect of Donepezil on Gait and Balance in Parkinson's Disease | A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease | Parkinson's Disease | Drug: Donepezil | Oregon Health and Science University | NULL | Recruiting | N/A | N/A | Both | 12 | Phase 4 | United States |
16 | JPRN-UMIN000005403 | 2011/04/01 | 08/04/2011 | A Multi-center Randomized Placebo-controlled Double-blinded Study for the Efficacy of Donepezil against Psychosis in Parkinson Disease | A Multi-center Randomized Placebo-controlled Double-blinded Study for the Efficacy of Donepezil against Psychosis in Parkinson Disease - EDAP study | Parkinson disease | 5mg of donepezil hydrochloride placebo | Designated Research, National Hospital Organization | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 142 | Phase 3 | Japan |
17 | JPRN-UMIN000003080 | 2010/01/01 | 30/01/2010 | Double Blind Study for Effects of Donepezil Hydrochloride on Parkinson's Disease | Double Blind Study for Effects of Donepezil Hydrochloride on Parkinson's Disease - EDP2010 study | Parkinson's disease | Donepezil hydrochloride (3mg for 2 weeks, 5mg for 2 weeks) Placebo | Clinical Research Center, Utano National Hospital, National Hospital Organization | NULL | Complete: follow-up complete | 40years-old | 75years-old | Male and Female | 30 | Not applicable | Japan |
18 | NCT00912808 (ClinicalTrials.gov) | October 2005 | 2/6/2009 | Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease | A Study of Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's | Parkinson's Disease | Drug: Donepezil;Drug: Sugar Pill (placebo) | Oregon Health and Science University | NULL | Completed | 21 Years | N/A | All | 23 | N/A | NULL |
19 | EUCTR2004-003355-39-AT (EUCTR) | 14/09/2004 | 08/10/2004 | A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia. | A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia. | Dementia associated with Parkinson's disease | Trade Name: Aricept 5 mg-Filmtabletten Product Name: Aricept 5mg-Filmtabletten | Eisai Limited | NULL | Not Recruiting | Female: yes Male: yes | 468 | Austria | |||
20 | NCT01327859 (ClinicalTrials.gov) | March 2003 | 30/3/2011 | Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia | A 52-week, Multicentre Open Label Extension Study of the Safety Tolerability and Efficacy of Donepezil (Aricept) in Parkinson's Disease (PD) Patients With Dementia | Parkinson's Disease;Dementia | Drug: Prior Donepezil 5mg;Drug: Prior Donzepezil 10mg;Drug: Prior Placebo | Eisai Inc. | NULL | Completed | 40 Years | N/A | Both | 357 | Phase 3 | United Kingdom |
21 | NCT00165815 (ClinicalTrials.gov) | August 2002 | 13/9/2005 | The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia | Dementia With Parkinson's Disease | Drug: ARICEPT | Eisai Limited | NULL | Completed | 40 Years | N/A | Both | Phase 3 | Germany;Ireland | ||
22 | NCT00030979 (ClinicalTrials.gov) | February 2002 | 15/2/2002 | Donepezil to Treat Dementia in Parkinson's Disease | Donepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover Trial | Parkinson Disease | Drug: Donepezil | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 28 | Phase 4 | United States |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2008-001940-38-IT (EUCTR) | 22/04/2008 | 14/04/2008 | Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function. - ND | Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function. - ND | patients affected by multiple sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis | Trade Name: ARICEPT INN or Proposed INN: Donepezil Trade Name: ARICEPT INN or Proposed INN: Donepezil | OSPEDALE S. RAFFAELE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
2 | EUCTR2005-003410-15-SE (EUCTR) | 21/11/2005 | 29/09/2005 | A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis. - Aricept in MS | A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis. - Aricept in MS | Multiple sclerosis is a devastating inflammation in the central nervous system and it can often give cognitive dysfunction, affecting memory, mental concentration. Lately it has been shown that the cognitive dysfunction has a big impact on life quality. Immunomodulatory medication can only partially limit the bouts but there is no effective cure at the moment. There is little options to treat the effects on higher functions for the moment. | Trade Name: Aricept 5 mg filmdragerade tabletter Product Name: Aricept 5 mg INN or Proposed INN: Donepezil Trade Name: Aricept 10 mg filmdragerade tabletter Product Name: Aricept 10 mg INN or Proposed INN: Donepezil | Neurology Unit | NULL | Not Recruiting | Female: yes Male: yes | 20 | Sweden | |||
3 | NCT00315367 (ClinicalTrials.gov) | September 2004 | 14/4/2006 | A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties | A Double-Blind, Crossover Trial of Aricept® in Memory-Impaired Patients With Multiple Sclerosis: A Phase IV Demonstration of Functional MRI (fMRI) as a Surrogate Marker of Brain Activity Associated With Improvement in Memory Function | Relapsing-Remitting Multiple Sclerosis | Drug: Donepezil HCI (drug) | Neurognostics | NULL | Completed | 18 Years | 65 Years | Both | 26 | Phase 4 | United States |
4 | NCT00062972 (ClinicalTrials.gov) | September 1999 | 18/6/2003 | Improving Memory in Patients With Multiple Sclerosis | Interventions to Improve Memory in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: donepezil;Drug: glucose | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | U.S. Department of Education | Withdrawn | 18 Years | 56 Years | All | 0 | Phase 3 | United States |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02927522 (ClinicalTrials.gov) | September 1, 2018 | 5/10/2016 | Donepezil Attenuate Postoperative Cognitive Dysfunction | Donepezil Attenuate Postoperative Cognitive Dysfunction in Aged Patients- A Multi-center, Case Control, Randomized Clinical Trail | Osteoarthritis;Femoral Head Necrosis;Rheumatoid Arthritis | Drug: Donepezil;Drug: Placebo | RenJi Hospital | Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine | Recruiting | 60 Years | N/A | All | 550 | Phase 3 | China |
78. Hypopituitarism
Clinical trials : 492 / Drugs : 341 - (DrugBank : 47) / Drug target genes : 45 - Drug target pathways : 100
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2005-001315-22-AT (EUCTR) | 09/03/2006 | 18/01/2006 | The effect of the cholinesterase inhibitor donepezil on organic and functional deficits related to growth hormone deficiency in old age. | The effect of the cholinesterase inhibitor donepezil on organic and functional deficits related to growth hormone deficiency in old age. | We plan to study healthy aging subjects. | Trade Name: Aricept Product Name: Aricept Product Code: Donepezil | Ludwig Boltzmann Gesellschaft | NULL | Not Recruiting | Female: yes Male: yes | 80 | Austria |
124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
Clinical trials : 12 / Drugs : 14 - (DrugBank : 5) / Drug target genes : 3 - Drug target pathways : 11
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2004-001162-40-IT (EUCTR) | 05/04/2005 | 21/09/2005 | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment. | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment. | Donezepil HCl for treatment of patients with CADASIL (Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy) who have cognitive impairment. MedDRA version: 6.1;Level: PT;Classification code 10009843 | Trade Name: ARICEPT 5*28 CPR 5 MG Product Name: NA Product Code: NA INN or Proposed INN: Donepezil | EISAI LTD UK | NULL | Not Recruiting | Female: yes Male: yes | Finland;United Kingdom;Germany;Spain;Italy;Sweden | ||||
2 | EUCTR2004-001162-40-SE (EUCTR) | 01/04/2005 | 03/02/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Finland;United Kingdom;Germany;Spain;Italy;Sweden | |||
3 | EUCTR2004-001162-40-ES (EUCTR) | 29/03/2005 | 20/01/2006 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4): | Finland;Spain;Germany;Italy;United Kingdom;Sweden | ||
4 | EUCTR2004-001162-40-FI (EUCTR) | 08/03/2005 | 28/12/2004 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Finland;Spain;Germany;Italy;United Kingdom;Sweden | ||
5 | EUCTR2004-001162-40-GB (EUCTR) | 24/02/2005 | 23/02/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4): | Finland;Spain;Germany;Italy;United Kingdom;Sweden | ||
6 | NCT00103948 (ClinicalTrials.gov) | February 2005 | 17/2/2005 | The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment | Cognitive Impairment | Drug: Aricept | Eisai Limited | NULL | Completed | 25 Years | 70 Years | Both | 165 | Phase 2 | United States;Australia;Spain;Canada;Finland;France;Germany;Italy;Sweden;Switzerland;United Kingdom |
7 | EUCTR2004-001162-40-DE (EUCTR) | 25/01/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Finland;Spain;Germany;Italy;United Kingdom;Sweden |
127. Frontotemporal lobar degeneration
Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000003239 | 2008/01/01 | 23/02/2010 | Influence of donepezil to behavioral and psychological symptoms of frontotemporal dementia | Influence of donepezil to behavioral and psychological symptoms of frontotemporal dementia - Donepezil in frontotemporal dementia | Frontotemporal dementia | Discontinuation of donepezil | National Hospital Organization Kikuchi Hospital | NULL | Complete: follow-up complete | 50years-old | 90years-old | Male and Female | 25 | Not selected | Japan |
156. Rett syndrome
Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00069550 (ClinicalTrials.gov) | September 2004 | 29/9/2003 | Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome | Pathogenesis of Rett Syndrome: Natural History and Treatment | Rett Syndrome | Drug: dextromethorphan;Drug: donepezil hydrochloride | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Recruiting | 1 Year | 15 Years | Both | 90 | Phase 3 | United States |
2 | NCT00004807 (ClinicalTrials.gov) | January 1995 | 24/2/2000 | Study of the Pathogenesis of Rett Syndrome | Rett Syndrome | Drug: dextromethorphan;Drug: topiramate;Drug: Donepezil | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Johns Hopkins University | Completed | N/A | 45 Years | Both | 120 | N/A | NULL |
206. Fragile X syndrome
Clinical trials : 108 / Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01120626 (ClinicalTrials.gov) | September 2009 | 7/5/2010 | Randomized Controlled Study of Donepezil in Fragile X Syndrome | Augmentation of the Cholinergic System in Fragile X Syndrome: A Double-Blind Placebo-Controlled Randomized Study of Donepezil | Fragile X Syndrome | Drug: donepezil;Drug: sugar pill | Stanford University | National Institute of Mental Health (NIMH);Autism Speaks | Completed | 12 Years | 29 Years | All | 45 | Phase 2 | United States |
2 | NCT00220584 (ClinicalTrials.gov) | July 2005 | 15/9/2005 | An Open-Label Trial of Donepezil in Fragile X Syndrome | An Open-Label Trial of Donepezil in Fragile X Syndrome | Fragile X Syndrome | Drug: donepezil | Stanford University | NULL | Completed | 14 Years | N/A | Both | 10 | Phase 1 | United States |